Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1659-1663
Published online before print July 1, 2004, doi: 10.1161/01.ATV.0000137415.67349.3c
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/9/1659    most recent
01.ATV.0000137415.67349.3cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shibata, H.
Right arrow Articles by Kobayashi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shibata, H.
Right arrow Articles by Kobayashi, S.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1659.)
© 2004 American Heart Association, Inc.

Vascular Biology

Correlation of NO Metabolites and 8-Iso-Prostaglandin F2a With Periventricular Hyperintensity Severity

Hiroshi Shibata; Toru Nabika; Hidehiko Moriyama; Junichi Masuda; Shotai Kobayashi

From the Departments of Laboratory Medicine (H.S., J.M.) and Functional Pathology (T.N.), Central Clinical Laboratory (H.M.), and Third Department of Internal Medicine (S.K.), School of Medicine, Shimane University, Izumo, and Shimane Institute of Health Science (T.N., J.M., S.K.), Izumo, Japan.

Correspondence to Toru Nabika, MD, Department of Functional Pathology, School of Medicine, Shimane University, Izumo 693-8501, Japan. E-mail nabika{at}med.shimane-u.ac.jp


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Objective— Oxidative stress and NO are thought to play important roles in arteriosclerosis pathogenesis, a major cause of white matter lesions in the brain. Therefore, we examined whether NO metabolites (NOx) and 8-iso-prostaglandin F2{alpha} (IsoP) levels in vivo correlated with the severity of periventricular hyperintensity (PVH) to evaluate potential roles of oxidative stress and NO in white matter lesions.

Methods and Results— Participants (687 males and 528 females) of a health-screening examination were recruited into the study. The plasma NOx and urinary IsoP levels were measured using the Griess method and ELISA, respectively. PVH was diagnosed on the basis of MRIs. In nonparametric univariate trend analyses, plasma NOx as well as aging, presence of hypertension and of lacunes, mean blood pressure, and high-density lipoprotein cholesterol showed highly significant monotone correlation with PVH severity (P≤0.01). By the multivariate ordinal regression analysis, the plasma NOx (P=0.002) and urinary IsoP (P=0.01) levels were found to be independent factors influencing the severity of PVH together with aging (P<0.001), presence of hypertension (P<0.001) and lacunes (P<0.001), and mean blood pressure (P=0.001).

Conclusions— Oxidative stress and NO have a close correlation with PVH severity.

Oxidative stress and NO levels were evaluated in a general population with or without mild periventricular hyperintensity under a cross-sectional study design. Serum NOx (NO metabolites) and urinary 8-iso-PG F2{alpha} (a marker for oxidative stress) correlated with the severity of periventricular hyperintensity in a multivariate analysis.


Key Words: lacunar infarction • nitric oxide • oxidative stress • white matter • small-vessel disease


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Cerebral white matter lesions (WMLs), including periventricular hyperintensity (PVH), are often found in the elderly during MRI examinations.1–3 The pathogenesis of WMLs is based on histopathologic changes such as subependimal gliosis, demyelination, small cavitations, and loss of axons deep in the white matter.1,2,4 Although the clinical significance of mild WMLs is controversial, the severe form is thought to relate closely to vascular dementia.1

Aging and hypertension are 2 established risk factors for WMLs.1,3 However, because not all hypertensive elderly people experience severe WMLs, other genetic or environmental factors may influence the risk of developing this cerebrovascular lesion.5 It is hypothesized that a major cause of WMLs is the occlusion and narrowing of peripheral penetrating arteries because of hyalinosis and fibrinoid necrosis, resulting in chronic ischemia or multiple minute infarctions.1,2,4 Considering this hypothesis, oxidative stress is a good candidate for an additional risk factor for WMLs.6 Evidence has indicated that excess oxidative stress is a risk factor not only for atherosclerosis in larger arteries but also for arteriosclerosis and remodeling of smaller arteries.7–9 Consistent with this hypothesis, Schmidt et al showed in their cross-sectional study that the plasma concentration of antioxidant {alpha}-tocopherol was correlated inversely with WML severity, although they did not adjust {alpha}-tocopherol levels with total cholesterol concentrations.10,11 Further, they also indicated in a separate study that a genotype of the paraoxonase 1 gene significantly influencedWML progression.12 Because paraoxonase 1 was proposed to hydrolyze oxidized lipids in vivo,13 this result further suggested the importance of oxidative stress in the pathogenesis and progression of WMLs.

Recently, 8-iso-prostaglandin F2{alpha} (IsoP), an end product of oxidized arachidonate, was proposed to be a good biological marker for oxidative stress in vivo.14,15 Its biological characteristics, such as chemical stability in urine, are suitable for large-scale epidemiological studies.15,16 Therefore, in this study, we examined whether the urinary IsoP level was correlated with the severity of PVH under a cross-sectional study design.

In addition to IsoP, we studied the plasma NO metabolites (NOx) concentration as a marker for the systemic level of NO. NO is a potent vasodilator thought to have a close connection with oxidative stress.17,18 The active NO level was reported to decrease under enhanced oxidative stress either through oxidation of NO itself or through inhibition of NOS activity by oxidative stress.18,19 Therefore, we hypothesized that the NO level in vivo might be a good candidate for a direct contributor to the vascular biology influencing WMLs under oxidative stress.

We report here that urinary IsoP and plasma NOx levels were correlated significantly with the severity of PVH in a multivariate analysis, which suggested that the increased oxidative stress and the decreased NO level in vivo were additional independent risk factors for WML progression.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
A total of 1215 consecutive participants (687 males and 528 females) who voluntarily visited the Shimane Institute of Health Science for a health screening examination between 1995 and 2000 were recruited into the study. In the interview, participants were asked about history of smoking, and medication for hypertension, diabetes mellitus, and hypercholesterolemia. A smoking index (SI; cigarettes per dayxyears) was calculated on the basis of the interview, and smoking status was categorized into 3 groups accordingly (nonsmoker SI=0; mild smoker SI<200; heavy smoker SI≥200).3

Plasma was collected after overnight fasting to measure total cholesterol, high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. The low-density lipoprotein cholesterol level was calculated using Friedman formula. Subjects with a serum TG concentration ≥4.52 mmol/L (11 males and 5 females) were excluded because of the formula requirement.20 Nitrite/nitrate (NOx) was measured in plasma by the Griess method using commercial kits (Cayman Chemical). Urine was collected on site and was kept frozen at –20°C until analyzed. Urinary IsoP was measured by an enzyme immunoassay using commercial kits (Cayman Chemical). IsoP concentrations in urine kept frozen at –20°C were stable for at least 6 months and after 5 rounds of freeze-thawing (data not shown). To avoid variance among different lots, kits from the same lot were used for measurement. IsoP levels were standardized with urinary creatinine.

PVH severity was rated as follows: 0, absent; 1, a small localized area of PVH at the frontal horn; 2, thin PVH surrounding the lateral ventricle; 3, thick PVH surrounding the lateral ventricle; and 4, marked diffuse PVH extending into the white matter.3,21 White matter hyperintensity (WMH) was rated with Fazekas criteria as described previously.10 Diagnostic criteria for lacunar infarction were described previously.21,22 Spotty areas <3 mm in diameter were diagnosed as état criblé. Diagnosis was based on T2-weighted (repetition time [TR] 2000 ms, echo time [TE] 24 ms) and proton density–weighted (TR 5000 ms, TE 96 ms) MRIs (0.2 T; Siemens) of transverse slices 7-mm thick.21 Typical images of PVH, WMH, and lacunar infarction are shown in Figure 1.



View larger version (98K):
[in this window]
[in a new window]
  		Figure 1. Typical MRIs of PVH, Fazekas WMH, and lacunar infarction (indicated with arrowheads).

Because TG, IsoP, and NOx levels were skewed toward lower values, log-transformed values were used in the analysis. Monotone trends of various factors along with PVH severity were evaluated with the nonparametric Jonckheere–Terpstra test or with an ordinal measure of association {gamma}. Independent effects of each factor on PVH severity were evaluated with the ordinal regression analysis. All statistical analyses were performed using SPSS (version 11.0; SPSS Inc.) and Statview (version 5.0; SAS Institute). All subjects agreed to participate in the study, which was approved by the local ethics committee.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
Demographic data on the population studied are listed in Table 1. A nonparametric trend analysis indicated highly significant monotone correlation of age, HDL-C, and mean blood pressure (MBP) with PVH severity. Presence of hypertension and lacunes showed a strong association with the severity as well. In addition, gender, body mass index (BMI), TG, and smoking status correlated significantly with PVH severity.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Demographic Data for the Population Studied

Figure 2 shows plasma NOx and urinary IsoP levels in the population studied. The monotone decrease of plasma NOx with the increase in PVH severity was significant (P=0.009). Although urinary IsoP showed a similar tendency to increase with a severity of 0 to 2, the monotone trend of changes did not reach a significant level (P=0.19). In contrast to PVH, neither plasma NOx nor urinary IsoP were associated significantly with lacune presence (Figure 2).



View larger version (21K):
[in this window]
[in a new window]
  		Figure 2. Correlation of plasma NOx and urinary IsoP levels with the severity of PVH and lacunar infarction. Plasma NOx and urinary IsoP levels were measured by the Griess method and ELISA, respectively. PVH severity was rated as described in Methods. Monotone trends of changes in NOx and IsoP were examined with the nonparametric Jonckheere–Terpstra test. Columns and lines indicate means and SEMs.

Because 9 factors were correlated significantly with PVH severity (Table 1), we performed a multivariate analysis including these factors as well as plasma NOx and urinary IsoP to test whether they have independent effects on severity. The results of the ordinal regression analysis are shown in Table 2. In addition to age, MBP, and the presence of hypertension and lacunes, plasma NOx and urinary IsoP levels showed independent effects on severity in the population studied. The other 5 factors (ie, male sex, BMI, HDL-C, TG [log-transformed], and smoking status), were excluded as independent factors through the analysis.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Parameters Independently Correlated With PVH Severity by the Ordinary Regression Analysis.

A logistic regression analysis indicated that only 2 factors, age and the presence of hypertension, showed a significant association with the presence of lacunes, excluding NOx and IsoP from factors associated independently with lacunar infarction (data not shown).


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
First, we showed that the plasma NOx level correlated significantly with PVH severity in this cross-sectional study. In general, one cannot infer a causal relationship between the factors analyzed under a cross-sectional study design. However, because it was not likely that PVH limited to the brain white matter influenced systemic plasma NOx levels, the present result may suggest that the plasma NOx decrease was related causally to PVH progression. The plasma NOx concentration is thought to represent the level of endogenous NO production when measured after overnight fasting.23,24 Hence, the reduced endogenous NO production may play a key role in PVH progression. Because NO not only acts as a potent vasodilator but also protects arteries from vascular remodeling,25 reduced NO levels in peripheral circulation might exacerbate stenosis because of the remodeling and then hypoperfusion in the white matter.

We also indicated that the urinary IsoP level was correlated positively with PVH severity in a multivariate analysis. The positive correlation of IsoP with the severity of PVH suggested a role for oxidative stress in PVH progression. Because this correlation was not evident in a univariate analysis, IsoP levels seemed influenced by other confounding factors. In fact, a weak but significant correlation was observed between IsoP and smoking status (Spearman {rho}=0.16; P<0.001). Another potential confounding factor was medication for hypertension or hypercholesterolemia. Some drugs, such as angiotensin II receptor antagonists and statins, are known to have substantial effects on oxidative stress.26,27 These drugs might add further noise to measurements of IsoP and NOx levels. Such medications as well as a small sample size (n=14) might explain the paradoxical relaxation of the monotonous trends in plasma NOx and urinary IsoP levels in subjects with PVH ≥3.

Concerning the mechanisms by which oxidative stress exacerbates WMLs, several animal studies have implied an important contribution by the endothelial NO synthase. Didion et al showed that a deficiency of the copper/zinc superoxide dismutase in mice inhibited endothelium-dependent vasodilatation in cerebral arterioles.28 In the stroke-prone spontaneously hypertensive rat, which is a model of hypertension-based cerebrovascular injury, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor ameliorated the severity of cerebrovascular damage through a reduction of oxidative stress and induction of eNOS activity.29

In addition to the possible contribution of NO, IsoP itself may be a factor detrimental to WMLs directly because IsoP is a potent vasoactive agent.15 In this context, it is of interest that a recent study by Brault et al indicated that IsoP injected intraventricularly induced periventricular damage, probably because of microvascular degeneration in rats.30 They also showed that addition of IsoP caused cell-type specific death of endothelial cells under the culture conditions. This in vitro observation suggests a direct detrimental effect of IsoP in WMLs.

Several studies comparing histological findings and MRIs in PVH indicated that the histological changes underlying mild PVH were not caused by ischemia, arguing that mild forms of PVH had no pathophysiological significance.1,31 According to this hypothesis, Schmidt et al included grade 1 and 2 PVH in a "normal" population in their study.10 In contrast, we did not include nonfocal vague hyperintensive lesions apart from periventricle in our criteria for PVH.21 Because this difference in diagnostic criteria may influence the results, we have retrospectively re-evaluated MRI films of the original cohort to classify the subjects with Fazekas criteria. The result indicated that the correlation between Fazekas WMH and PVH was moderate (Spearman {rho}=0.33; P<0.0001; n=1199), and accordingly, monotonous trends of NOx or IsoP changes were not apparent with Fazekas grading (data not shown). In contrast, a preliminary evaluation of another cohort recruited recently indicated a better correlation between PVH and Fazekas WMH (Spearman {rho}=0.68; P<0.0001; n=388). Because MRI with higher power (1.5 T) was used in the recent cases, this discrepancy may be attributable to difficulties in evaluation of minute "spots" in the deep white matter on old films taken at low power. Supporting this, most of the subjects in the original cohort (88%) were classified into Fazekas grade 0 compared with 68% in the "recent" cohort. A replication study comparing Fazekas WMH and PVH in 1 large cohort is essential to address this issue.

Although evidence of a correlation between NOx/IsoP and Fazekas WMH was not obtained in the study, the observed correlation of NOx/IsoP with PVH severity may still have some pathophysiological significance. PVH was interpreted to reflect a normal structure through a histopathologic evaluation.30 However, the evaluation was based on relatively small sample sizes, leaving a possibility that some "pathological" PVH cases were mixed with normal cases. In fact, a histopathologic study indicated arteriosclerotic lesions in milder forms of PVH,32 which were hypothesized to be related causally to the lesion by some authors.33 In addition, the present study indicated that even for the milder forms, several parameters correlated with the severity of PVH (Tables 1 and 2 Up), suggesting some pathophysiological background underlying PVH progression. This view was further supported by our recent prospective study showing that the PVH severity was a good predictor of symptomatic strokes.34

In contrast to PVH, neither NOx nor IsoP levels influenced the presence of lacunar infarction. This result was rather unexpected because lacunar infarction and WMLs were thought to share the same etiologic background.35 Our observation may be interpreted as follows. (1) In the lacunar infarctions, the NO level or oxidative stress has a minor etiologic role when compared with WMLs. Although WMLs are a chronically progressing diffuse change, lacunar infarctions may be more accidental and acute changes.4 Thus, even if the same etiologies are shared, some additional factors may contribute more to lacune pathogenesis.1,4 (2) Lacunar infarction stratification in the present study was not adequate to detect effects of NO or oxidative stress. Although we stratified our population by the presence or absence of lacunes, it may be necessary to use other stratifications such as lacune size or number.

There are some limitations to this study. First, IsoP levels were determined in spot urine samples by ELISA in this study instead of using a 24-hour collection of urine and gas chromatography (GC)/mass spectrometry (MS) measurements. Second, plasma NOx levels after overnight fasting might still be under some influence of dietary NOx.36 These limitations were a consequence of the study design. The population used here consisted of otherwise healthy subjects attending a health examination voluntarily. Therefore, it was impractical to collect urine for 24 hours or to control dietary NOx using diets with low NOx contents before plasma collection.36 In addition, GC/MS is difficult to apply to a large number of samples. In spite of these limitations, IsoP levels measured by ELISA as well as the NOx levels after overnight fasting were applied successfully to recent clinical and epidemiological studies.16,24,31,37,38 Another limitation was, as discussed above, a lack of information on antihypertensive and antihypercholesterolemic medications in the cohort. It was difficult to obtain precise information on what type of medications they received in the interview. However, as pointed out in the recent study, these limitations might reduce the signal-to-noise ratio of the study, producing false-negative results.16

In summary, the present study provided new epidemiological evidence implying possible roles for oxidative stress and NO in WML progression. The results warrant further pathophysiological and epidemiological study.


*    Acknowledgments
 
The authors appreciate all the efforts made by the staff of the Shimane Institute of Health Science in pursuit of this work. This study was supported partly by a grant from the Shimane Institute of Health Science.

Received April 11, 2004; accepted June 14, 2004.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Martinez-Lage P, Hachinski V. Multi-infarct dementia. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis, and Management. Philadelphia, Pa: Churchill Livingstone; 1998: 875–894.
  2. van Swieten JC, van den Hout JHW, van Ketel BA, Hijdra A, Wokke JHJ, van Gijn J. Periventricular lesions in the white matter on magnetic resonance imaging in the elderly. Brain. 1991; 114: 761–774.[Abstract/Free Full Text]
  3. Kobayashi S, Okada K, Yamashita K. Incidence of silent lacunar lesion in normal adults and its relation to cerebral blood flow and risk factors. Stroke. 1991; 22: 1379–1383.[Abstract/Free Full Text]
  4. Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc Dis. 2002; 13 (suppl 2): 11–15.
  5. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998; 29: 1177–1181.[Abstract/Free Full Text]
  6. Schmidt R, Schmidt H, Kapeller P, Lechner A, Fazekas F. Evolution of white matter lesions. Cerebrovasc Dis. 2002; 13 (suppl 2): 16–20.[CrossRef]
  7. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997; 28: 652–659.[Abstract/Free Full Text]
  8. Griendling KK, Alexander W. Oxidative stress and cardiovascular diseases. Circulation. 1997; 96: 3264–3265.
  9. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000; 18: 655–673.[CrossRef][Medline] [Order article via Infotrieve]
  10. Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals: correlations with plasma concentrations of naturally occurring antioxidants. Stroke. 1996; 27: 2043–2047.[Abstract/Free Full Text]
  11. Traber MG. Measurement of lipid-soluble vitamins–further adjustment needed? Lancet. 2000; 355: 2013–2014.[CrossRef][Medline] [Order article via Infotrieve]
  12. Schmidt R, Schmidt H, Fazekas F, Kapeller P, Roob G, Lechner A, Kostner GM, Hartung H-P. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol. 2000; 20: 1811–1816.[Abstract/Free Full Text]
  13. Laplaud PM, Dantoine T, Chapman MJ. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin Chem Lab Med. 1998; 36: 431–441.[CrossRef][Medline] [Order article via Infotrieve]
  14. Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev. 2000; 32: 377–385.[CrossRef][Medline] [Order article via Infotrieve]
  15. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997; 17: 2309–2315.[Abstract/Free Full Text]
  16. Keaney JF, Larson MG, Vasan RS, Wilson PWF, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003; 23: 434–439.[Abstract/Free Full Text]
  17. Bloodsworth A. O’Donnell VB, Freeman BA. Nitric oxide regulation of free radical- and enzyme-mediated lipid and lipoprotein oxidation. Arterioscler Thromb Vasc Biol. 2000; 20: 1707–1715.[Abstract/Free Full Text]
  18. Kitiyakara C, Wilcox CS. Antioxidants for hypertension. Curr Opin Nephrol Hypertens. 1998; 7: 531–538.[Medline] [Order article via Infotrieve]
  19. Ota Y, Kugiyama K, Sugiyama S, Ohgushi M, Matsumura T, Doi H, Ogata N, Oka H, Yasue H. Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract-role of free radicals and attenuation by captopril. Atherosclerosis. 1997; 131: 195–202.[CrossRef][Medline] [Order article via Infotrieve]
  20. Nabika T, Nasreen S, Kobayashi S, Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis. 2002; 165: 201–204.[CrossRef][Medline] [Order article via Infotrieve]
  21. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke. 1997; 28: 1932–1939.[Abstract/Free Full Text]
  22. Notsu Y, Nabika T, Park H-Y, Masuda J, Kobayashi S. Evaluation of genetic risk factors for silent brain infarction. Stroke. 1999; 30: 1881–1886.[Abstract/Free Full Text]
  23. Rhodes PM, Leone AM, Francis PL, Struthers AD, Moncada S. The L-arginine:nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun. 1995; 209: 590–596.[CrossRef][Medline] [Order article via Infotrieve]
  24. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17ß-estradiol and norethisterone acetate: a two-year follow-up study. Hypertension. 1995; 25: 848–853.[Abstract/Free Full Text]
  25. Rudic DR, Sessa WC. Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am J Hum Genet. 1999; 64: 673–677.[CrossRef][Medline] [Order article via Infotrieve]
  26. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003; 23: 729–736.[Abstract/Free Full Text]
  27. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol. 2003; 42: 911–913.[Free Full Text]
  28. Didion SP, Ryan MJ, Didion LA, Fegan PE, Sigmund CD, Faraci FM. Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice. Circ Res. 2002; 91: 938–944.[Abstract/Free Full Text]
  29. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N, Hirata K, Yokoyama M. HMB-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke. 2003; 34: 157–163.[Abstract/Free Full Text]
  30. Brault S, Martinez-Bermudez AK, Marrache AM, Gobeil F, Hou X, Beauchamp M, Quiniou C, Almazan G, Lachance C, Roberts J II, Varma DR, Chemtob S. Selective neuromicrovascular endothelial cell death by 8-iso-prostaglandin F2a. Stroke. 2003; 34: 776–782.[Abstract/Free Full Text]
  31. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993; 43: 1683–1689.[Abstract/Free Full Text]
  32. Chimowitz MI, Estes ML, Furlan AJ, Awad IA. Further observations on the pathology of subcortical lesions identified on magnetic resonance imaging. Arch Neurol. 1992; 49: 747–752.[Abstract]
  33. Pantoni L, Garcia JH. Significance of cerebral white matter abnormalities 100 years after Binswanger’s report: a review. Stroke. 1995; 26: 1293–1301.[Abstract/Free Full Text]
  34. Bokura H, Kobayashi S, Yamaguchi S, Nagai A, Iijima K, Takahashi K. Silent brain infarction and white matter lesions are risk factors for stroke and cardiovascular accidents: prospective cohort study. Stroke. 2004; 35: 316.
  35. Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G, Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM, Esterbauer H. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J Neurol Sci. 1997; 152: 15–21.[CrossRef][Medline] [Order article via Infotrieve]
  36. Jungersten L, Edlund A, Petersson A-S, Wennmalm A. Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol. 1996; 16: 369–379.[Medline] [Order article via Infotrieve]
  37. Roberts CK, Vaziri ND, Barnard J. Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability. Circulation. 2002; 106: 2530–2532.[Abstract/Free Full Text]
  38. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T, Igari J. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun. 1998; 245: 190–193.[CrossRef][Medline] [Order article via Infotrieve]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/9/1659    most recent
01.ATV.0000137415.67349.3cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shibata, H.
Right arrow Articles by Kobayashi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shibata, H.
Right arrow Articles by Kobayashi, S.

ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.